Alcon Q3 net income rises 10% to $260 million; Q3 net sales climb 5% to $2.7 billion

• Alcon’s third-quarter 2026 net income rose 10% year over year to $260 million.
• Quarterly net sales climbed 5% year over year to $2.7 billion.
• Nine-month 2026 net income fell 41% to $449 million; the period included a $402 million charge for discontinuing PowerVision programs.
• The recently announced acquisition of Neurotech Pharmaceuticals strengthens its retinal-disease capabilities with ENCELTO.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alcon AG published the original content used to generate this news brief on November 10, 2026, and is solely responsible for the information contained therein.